- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01768169
Study of Metabolic Syndrome Use Omega-3 Fatty Acids and Low Fat Meal
Phase 2 Study of Metabolic Syndrome Use Omega-3 Fatty Acids and Low Fat Meal Replacements
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The metabolic syndrome is a common condition in which different degrees of hypertension, impaired glucose tolerance, atherogenic dyslipidemia, and central fat accumulation, as well as prothrombotic and proinflammatory states cluster together in the same individual. The modified National Cholesterol Education Program, Adult Treatment Panel III guidelines defined the metabolic syndrome subjects as individuals with 3 or more following criterion:
- Waist circumference: in male ≥90 cm and female ≥80 cm
- Raised triglycerides: > 150 mg/dL
- Reduced HDL cholesterol: <40 mg/dL in males, <50 mg/dL in females
- Raised blood pressure: systolic blood pressure >130 or diastolic blood pressure >85 mmHg
- Raised fasting plasma glucose: (FPG)>100 mg/dL
Changes in macronutrient composition have been used to promote weight loss and enhance insulin sensitivity, independent of an emphasis on overall calorie ingestion. Protective effects of fish intake on the development of insulin resistance has been reported in prospective epidemiological studies. Further, long chain omega-3 PUFAs supplementation may improve insulin sensitivity in patients with impaired glucose tolerance and in patients with T2DM.
However, this has not been clearly demonstrated in an intervention trial in Taiwan. Furthermore, the effect of supplementation of long chain omega-3 PUFAs on metabolic risk factors and insulin resistance, except for demonstrated benefit in terms of decreased triglycerides, needs further investigation among Asians.
This 13-week, randomized controlled study will assign approximately 200 subjects meeting criteria for the Metabolic Syndrome (50 each) to the following four arms 1) Standard Taiwan Diet plan; 2) Herbalife meal replacement diet program (Low fat diet); 3) Standard Taiwan Diet plan plus healthy oil supplement (Herbalifeline®) and 4) Herbalife meal replacement plan (Low fat diet) plus healthy oil supplement (Herbalifeline®). All participants will meet with a registered dietitian to assist them with their diet efforts.
In this study, we aim to study the effects of low fat diet with reduced omega-6 PUFAs alone and the same low fat diet with omega-3 fatty acids supplementation on cardiometabolic profile and circulating fatty acid profiles in subjects with the metabolic syndrome.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- Taipei Mecical University Hospital
-
Contact:
- Wen-Yi Cheng
- Phone Number: 886223711458
- Email: rhoda2891@hotmail.com
-
Principal Investigator:
- Shih-Yi Huang, Ph.D.
-
Sub-Investigator:
- Hsiu-Yue Su, MSc
-
Sub-Investigator:
- Chien-Tien Su, Ph.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 30 to 65 years
- Female subjects must have a negative pregnancy test at screening, must be surgically sterile or at least 6 months postmenopausal or must use a form of birth control measure.
- BMI of 24 to 40 kg/m2 inclusive.
- Subjects must be in good health other than having metabolic syndrome as determined by medical history, physical examination, and screening clinical laboratory including chemistry panel and CBC.
- Must have stable smoking habits (or be now-smokers) for at least 6 months prior to screening and agree not to intend to change such habits during the course of the study.
- Subjects requiring the regular use of any prescription medication may be admitted to the study providing the dose is stable.
- Ethical subjects only will be admitted who are likely to comply with all visits and instructions. This will be determined in the screening phase.
- Body weight must be stable within 2% of change in the last 3 months.
- Subject must sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or randomization. A subject will be excluded for any condition that might compromise the ability to give truly informed consent for participation in the study.
Exclusion Criteria:
- Diabetes
- nown or documented coronary heart disease (CHD) (including ECG consistent with prior myocardial infraction), cerebrovascular accident (including transient ischemic attack), peripheral vascular disease (including symptoms of claudication)
- Angina or other chest pain that may indicate CHD
- Clinically significant neoplastic, cardiovascular, hepatic, renal, metabolic, endocrine (untreated or unstable), or psychiatric (untreated or unstable)
- Known abnormal liver function tests greater than 3X upper limit of normal
- Smoker, illicit drug use, or excessive alcohol use
- Medications: Lipid lowering therapy, daily NSAID or greater than 325 mg ASA (PRN use ok), clopidogrel (or equivalent), Coumadin, omega-3 fatty acid supplement, other investigational drugs within 30 days of study entry, high omega-3 fatty acid content in diet within past three months
- Pregnancy or planning pregnancy during the study period
- Sensitivity or allergy to fish
- Subjects who had undergone bypass procedure.
- Any debilitating disease such as tuberculosis, HIV etc.
- Unwillingness to give written informed consent for participation in the study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
fish oil capsule
10 capsules per day will provide 2130 mg of EPA (1280 mg) and DHA (850 mg)
|
500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolic syndrome index
Time Frame: Day 1 and up to 12 weeks
|
|
Day 1 and up to 12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shih-Yi Huang, Ph.D, Taipei Medical University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- omega-3 fatty acids
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Mayo ClinicCompleted
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on fish oil capsule
-
University GhentJimma University; Nutricia Research Fundation; VLIR Institutional University... and other collaboratorsCompletedChild MalnutritionEthiopia
-
Nutrition 21, Inc.UnknownSigns and Symptoms, DigestiveUnited States
-
University of Mississippi, OxfordWalgreen'sCompleted
-
Second Xiangya Hospital of Central South UniversityXiangya Hospital of Central South UniversityUnknown
-
University of RochesterGlaxoSmithKline; Albany College of Pharmacy and Health SciencesTerminated
-
University of CopenhagenAnjo A/SCompletedObesity | Cardiovascular Disease | Metabolic Syndrome | Growth | Blood Pressure
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI); GlaxoSmithKline; eCardio DiagnosticsCompletedAtrial FibrillationUnited States
-
DSM Nutritional Products, Inc.Completed
-
National Science Council, TaiwanCompletedMajor Depressive DisorderTaiwan
-
Rigshospitalet, DenmarkDanish Child Cancer FoundationRecruitingLeukemia, Acute LymphoblasticDenmark